Skip to main content
. 2014 Jul 1;9(7):e100947. doi: 10.1371/journal.pone.0100947

Figure 2. Either stable or transient depletion of GSK3A abolishes drug resistance of p53-null colon carcinoma cell lines.

Figure 2

A) colony assay of 5FU-treated HCT116p53KO-pRS and -pRSGSK3A cells. Cells were trypsinized and reseeded at low density 12 hours after 200 µM 5FU treatment. Colony formation was assessed 2 weeks after the reseeding. B) percentage of cell death of HCT116p53KO-pRS, -pRSGSK3A and -pRSGSK3B cells treated for 72 hrs with 200 µM 5FU. Drug sensitive HCT116 cells were used as a positive control. C) percentage of cell death of HCT116p53KO-pRS, -pRSGSK3A and -pRSGSK3B cells treated for 72 hrs with 50 µM Oxaliplatin (OxPt). Drug sensitive HCT116 cells were used as a positive control. D) percentage of cell death of HCT116p53KO upon GSK3A transient silencing and treatment with 200 µM 5FU (72 hrs). In the inset: lysates of HCT116p53KO cells transfected with luciferase (luc)- or GSK3A-specific siRNAs were harvested 24 hs after silencing and GSK3A levels checked by western blot.